Sign Up to like & get recommendations! 0
Published in 2017 at "Cancer Medicine"
DOI: 10.1002/cam4.1028
Abstract: The aim of this work is to assess if cumulative dose (CD) and dose intensity (DI) of everolimus may affect survival of advanced pancreatic neuroendocrine tumors (PNETs) patients. One hundred and sixteen patients (62 males… read more here.
Sign Up to like & get recommendations! 1
Published in 2019 at "Cancer Medicine"
DOI: 10.1002/cam4.2232
Abstract: Although the postoperative recurrence rate for pancreatic neuroendocrine tumors (PNETs) is reported to be 13.5%‐30%, the paucity of valuable biomarkers to predict recurrence poses a problem for the early detection of relapse. Hence, this study… read more here.
Sign Up to like & get recommendations! 0
Published in 2019 at "Cancer Medicine"
DOI: 10.1002/cam4.2431
Abstract: Patients who suffer from gastro‐entero‐pancreatic neuroendocrine neoplasms (GEP‐NENs) often present with liver metastatic disease. The efficacy of primary tumor resection (PTR) for these patients remains controversial due to the relatively heterogeneous behavior of the primary… read more here.
Sign Up to like & get recommendations! 0
Published in 2017 at "Diagnostic Cytopathology"
DOI: 10.1002/dc.23635
Abstract: Mitotic count in hematoxylin‐eosin stained slides and Ki‐67 index allow stratification of patients for prognosis and therapeutic decision making in pancreatic neuroendocrine tumors (PNETs). However, the utility of Ki‐67 determination in cytological material and its… read more here.
Sign Up to like & get recommendations! 0
Published in 2023 at "Diagnostic cytopathology"
DOI: 10.1002/dc.25154
Abstract: BACKGROUND The recently described sclerosing variant of pancreatic neuroendocrine tumor (spNET) shows prominent stromal fibrosis and decreased tumor cellularity in surgical pathology specimens. Although prognostic data are currently ambivalent, some studies have reported metastatic disease… read more here.
Sign Up to like & get recommendations! 1
Published in 2022 at "International Journal of Cancer"
DOI: 10.1002/ijc.34294
Abstract: Clinically effective methods to predict the efficacy of sunitinib, for patients with metastatic or locally advanced pancreatic neuroendocrine tumors (panNET) are scarce, making precision treatment difficult. This study aimed to develop and validate a computed… read more here.
Sign Up to like & get recommendations! 0
Published in 2020 at "Journal of Hepato-Biliary-Pancreatic Sciences"
DOI: 10.1002/jhbp.739
Abstract: We examined therapeutic strategies for pancreatic neuroendocrine neoplasm (pNEN) associated with MEN1 (M‐pNEN) by investigating clinicopathological features and menin expression. read more here.
Sign Up to like & get recommendations! 0
Published in 2019 at "Journal of Surgical Oncology"
DOI: 10.1002/jso.25481
Abstract: To determine short‐ and long‐term oncologic outcomes after minimally invasive distal pancreatectomy (MIDP) with open distal pancreatectomy (ODP) for the treatment of pancreatic neuroendocrine tumor (pNET). read more here.
Sign Up to like & get recommendations! 0
Published in 2019 at "Journal of Surgical Oncology"
DOI: 10.1002/jso.25689
Abstract: The benefit derived from lymph node dissection (LND) in patients with pancreatic neuroendocrine tumors (pNETs) based on clinicopathological characteristics remains unclear. read more here.
Sign Up to like & get recommendations! 1
Published in 2021 at "Journal of surgical oncology"
DOI: 10.1002/jso.26667
Abstract: BACKGROUND AND OBJECTIVES Pancreatic neuroendocrine tumors (PNETs) represent a rare form of pancreatic cancer. Racial/ethnic disparities have been documented in pancreatic ductal adenocarcinoma, but health disparities have not been well described in patients with PNETs.… read more here.
Sign Up to like & get recommendations! 1
Published in 2022 at "Journal of Surgical Oncology"
DOI: 10.1002/jso.26928
Abstract: To define surgical outcomes of patients with high‐grade gastro‐entero‐pancreatic neuroendocrine neoplasm grade G3 (GEP‐NEN G3). read more here.